Pharma & Biotech

For over a decade, the shares of Rxelite have existed in a state of suspended animation on the public markets....

Biotechnology firm Ocugen has completed patient enrollment for the pivotal Phase 3 clinical trial of its lead candidate, OCU400, a...

Danaher Corporation has outlined a definitive strategic roadmap targeting the 2026 fiscal year. While acknowledging specific regional headwinds, the company's...

The healthcare giant Johnson & Johnson is pursuing a dual strategy to enhance patient access and advance its pipeline. In...

Axsome Therapeutics is gearing up for a substantial scaling of its commercial operations. The biopharmaceutical firm is placing a significant...

A significant legal case commenced in Chicago on March 4, targeting global healthcare company Abbott Laboratories. The core of the...

Italian biopharmaceutical firm Newron SpA has fortified its financial position, ensuring the advancement of its key clinical programs. The company...

Telix Pharmaceuticals is approaching a pivotal period in its corporate development. The company has set its sights on generating nearly...

With a notable absence of recent company-specific announcements, Animalcare's stock is currently trading in a quiet phase. This lack of...

Bayer's recently published annual report for 2025 delivers an unambiguous message: the legal risks associated with glyphosate continue to overshadow...